MedTrace Logo

Efficacy and Safety of Camrelizumab in Real-World Study

NCT04631146 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 450

Last updated 2020-11-17

No results posted yet for this study

Summary

This observational real-world study is designed to evaluate the efficacy and safety of camrelizumab for the treatment of Chinese NSCLC patients.

Conditions

Interventions

DRUG

Camrelizumab

PD-1 inhibitors

Sponsors & Collaborators

  • Guangdong Association of Clinical Trials

    lead OTHER

Principal Investigators

  • Wu Yilong, Doctor · Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2021-06-30
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04631146 on ClinicalTrials.gov